Pancreatic Cancer Research

ResearcherNantong UniversityActive in the last 2 years

Jun Lü

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7343-9706; OpenAlex author ID A5100617401. Sources: OpenAlex.

Their work

Papers
22 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 8 papers · 2021: 5 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 22

  1. MLH1 Inhibits Metastatic Potential of Pancreatic Ductal Adenocarcinoma via Downregulation of GPRC5C. First author DOI 10.1016/j.labinv.2024.102107↗
  2. FGFR3 Nuclear Translocation Contributes to Proliferative Potential and Poor Prognosis in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000002056↗
  3. Elevated TIAM2 expression promotes tumor progression and is associated with unfavorable prognosis in pancreatic cancer. Co-author DOI 10.1080/00365521.2020.1853806↗
  4. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic… First author DOI 10.1097/mpa.0000000000001892↗
  5. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients… Co-author DOI 10.1111/jgh.15244↗
  6. Identification of Key Genes Mutations Associated With the Radiosensitivity by Whole Exome Sequencing in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.697308↗
  7. Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.812785↗
  8. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  9. Photodynamic therapy of pancreatic cancer: Where have we come from and where are we going? Co-author DOI 10.1016/j.pdpdt.2020.101876↗
  10. Ubiquitin-specific protease 4 predicts an unfavorable prognosis and promotes malignant behaviors in vitro in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2020.112317↗
  11. Matrix Metalloproteinase 11 as a Novel Tumor Promoter and Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000001583↗
  12. Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer. Co-author DOI 10.1186/s12935-020-01550-y↗
  13. Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.00576↗
  14. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review. Co-author DOI 10.3389/fonc.2020.01466↗
  15. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? Co-author DOI 10.3389/fonc.2020.576399↗
  16. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2018.11.026↗
  17. Knockout of Acinar Enriched microRNAs in Mice Promote Duct Formation But Not Pancreatic Cancer. Co-author DOI 10.1038/s41598-019-47566-x↗
  18. Research progress on circularRNAs in pancreatic cancer: emerging but promising. Co-author DOI 10.1080/15384047.2019.1617563↗
  19. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma. First author DOI 10.1002/jso.25253↗
  20. A novel prognostic marker and immunogenic membrane antigen: prohibitin (PHB) in pancreatic cancer. Co-author DOI 10.1038/s41424-018-0044-1↗
  21. E‑cadherin is downregulated by microenvironmental changes in pancreatic cancer and induces EMT. Co-author DOI 10.3892/or.2018.6528↗
  22. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.canlet.2017.02.036↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li Zhou · 17 shared papers, 2017–2024 · strength 2.15
  2. Junchao Guo · 13 shared papers, 2017–2022 · strength 1.49
  3. Bolun Jiang · 10 shared papers, 2020–2022 · strength 1.30
  4. Lei You · 10 shared papers, 2017–2022 · strength 1.11
  5. Zhiyong Liang · 10 shared papers, 2017–2022 · strength 1.11
  6. Yizhi Wang · 7 shared papers, 2020–2021 · strength 0.91
  7. Yizhi Wang · 5 shared papers, 2019–2022 · strength 0.63
  8. Jianzhou Liu · 2 shared papers, 2021–2024 · strength 0.39
  9. Junchao Guo · 3 shared papers, 2020 · strength 0.37
  10. Yu-Pei Zhao · 4 shared papers, 2017–2020 · strength 0.35
  11. Yupei Zhao · 3 shared papers, 2018–2020 · strength 0.32
  12. Bingqi Li · 3 shared papers, 2018–2019 · strength 0.30
  13. Wen-Jing Liu · 1 shared paper, 2024 · strength 0.28
  14. Taiping Zhang · 3 shared papers, 2017–2020 · strength 0.24
  15. Gary Guishan Xiao · 2 shared papers, 2020 · strength 0.22
  16. Bangbo Zhao · 2 shared papers, 2018 · strength 0.19
  17. Zhigang Zhang · 2 shared papers, 2017–2020 · strength 0.15
  18. Junchao Guo · 1 shared paper, 2021 · strength 0.13
  19. Xu Zhang · 1 shared paper, 2020 · strength 0.13
  20. Xi Zoë Zhong · 1 shared paper, 2020 · strength 0.13
  21. Bin Hu · 1 shared paper, 2021 · strength 0.12
  22. Zheng Wu · 1 shared paper, 2021 · strength 0.12
  23. Yongrui Bai · 1 shared paper, 2021 · strength 0.12
  24. Yu Wang · 1 shared paper, 2021 · strength 0.11
  25. Bowen Huang · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.